Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
European Journal of Haematology|March 15, 2023
Validation of National Early Warning Score and Quick Sequential (sepsis-related) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapyChiara Frairia, Barbara Nicolino, Carolina Secreto, et al.
Frontiers in Immunology|June 2, 2020
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical PracticeMarco Cerrano, Marco Ruella, Miguel-Angel Perales, et al.
Haematologica|May 14, 2026
Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in ItalyMassimo Breccia, Alessandra Iurlo, Fabrizio Pane, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 13, 2023
Levofloxacin Prophylaxis Versus no Prophylaxis in Acute Myeloid Leukemia During Post-Induction Aplasia: a Single Center StudyIrene Urbino, Chiara Frairia, Alessandro Busca, et al.
Expert Review of Hematology|May 21, 2026
T-cell acute lymphoblastic leukemia in adults: current treatment approaches and future perspectivesLorenzo Celona, Eleonora Boscaro, Giulia Berutto, et al.
Clinical and Translational Medicine|April 25, 2025
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid LeukemiaManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Annals of Hematology|February 7, 2022
Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational studyFederica Martella, Marco Cerrano, Daniela Di Cuonzo, et al.
Hematological Oncology|August 8, 2025
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE StudyAlessandra Iurlo, Massimo Breccia, Fabio Stagno, et al.
Leukemia|January 22, 2026
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemiaMichela Ansuinelli, Nadia Peragine, Maria Stefania De Propris, et al.
Haematologica|December 7, 2023
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive diseaseSabine Kayser, Chiara Sartor, Fabio Giglio, et al.
Pageof 7